Huzatin Tablet 150mg (Nizatidine)

Adult dose

1. Treatment of active gastric and duodenal ulcers Adults: Administer nizatidine 300mg once daily at bedtime, or 150mg twice daily, orally in the morning and evening. Most ulcers heal within 4 weeks, but treatment may be continued for up to 8 weeks if necessary. 2. Prevention of duodenal ulcer recurrence Adults: After healing of a duodenal ulcer, administer 150mg orally once daily at bedtime. Treatment may be continued for up to 1 year; results of longer-term treatment are not known. 3. Gastroesophageal reflux disease Adults: Administer 150mg orally twice daily, in the morning and evening. Treatment may be continued for up to 12 weeks. 4. Improvement of gastric mucosal lesions Adults: Administer 150mg orally twice daily, in the morning and evening, for 2 weeks. 5. Dosage adjustment for patients with severe renal impairment Dosage for patients with renal impairment should be adjusted by reducing the dose as follows. Active duodenal ulcer, gastroesophageal reflux disease (GERD), benign gastric ulcer: Creatinine clearance 20~50 ml/min: 150mg daily; < 20 ml/min: 150mg every other day Maintenance therapy: Creatinine clearance 20~50 ml/min: 150mg every other day; < 20 ml/min: 150mg every 3 days Some elderly patients may have creatinine clearance below 50mL/min. Based on pharmacokinetic data in patients with renal impairment, the dosage should also be reduced according to the degree of renal impairment in these patients.

This medication should not be administered to patients who have had hypersensitivity reactions to H2-receptor antagonists. Patients with a history of drug allergy reactions should use it cautiously. Patients with poor liver function or kidney issues should adjust the dosage or extend the interval of administration for this medication. If allergic symptoms such as rash, itching, difficulty breathing, or laryngeal edema occur while using this medication, it should be discontinued immediately. Routine blood tests are important as there can be changes in anemia or blood levels of leucocytes and platelets. Digestive symptoms like constipation, diarrhea, dry mouth, and nausea may occur, so caution is advised. Liver function test results may increase, and serious liver problems like hepatitis or jaundice may occur, albeit rarely. Mental confusion, headache, drowsiness, or dizziness may appear, so caution is needed. There can be episodes of tachycardia. In women, gynecomastia may occur rarely, along with reports of erectile dysfunction or decreased libido. Skin reactions like rash, hives, and sweating may appear, so it’s important to report any abnormal symptoms. Though not related to gout or kidney stones, hyperuricemia may occur, along with symptoms like fever or muscle pain. Symptoms of gastric cancer may be masked, necessitating confirmation that it is not a malignant tumor before use. This medication is primarily eliminated through the kidneys, so patients with reduced kidney function should decrease the dosage and closely monitor treatment progress. There is insufficient pharmacokinetic research on patients with liver and kidney problems, necessitating caution. This medication has relatively few interactions with specific drugs, but when used with high-dose aspirin, the serum salicylate concentration may increase. Women who are pregnant or may become pregnant should carefully consider the effects of this medication on the fetus before starting treatment. Lactating women should use it only if necessary, as this medication may be secreted in small amounts in breast milk. Safety and efficacy in children have not been established, so caution is required in their use. Elderly patients are at higher risk of decreased kidney function, so kidney function tests should be conducted before administration, and their kidney condition should be closely monitored during treatment. This medication may cause false-positive results in urobilinogen tests, so this should be noted during testing. Overdose may result in symptoms such as vomiting, diarrhea, and miosis, and necessary measures like inducing vomiting or gastric lavage should be taken if needed. This medication is not removed by hemodialysis; therefore, alternative treatment methods are required in case of overdose. Though no carcinogenicity or genotoxicity have been reported in animal studies with long-term high-dose use, some changes may be noted in the liver, so caution is advised. In pregnant animal studies, high-dose treatment has reported some fetal abnormalities, so pregnant women should be cautious in its use. In lactating animals, growth inhibition has been observed, so nursing mothers should carefully decide on drug administration. Rare side effects related to erectile dysfunction have been reported with this medication, so consult a doctor if there are any changes in sexual function.

• Rash
• itching
• bronchial asthma
• laryngeal edema
• symptoms of anaphylaxis
• anemia
• leukopenia
• neutrophilia
• thrombocytopenic purpura
• constipation

This medication should be stored in a sealed container to protect it from air and moisture. Additionally, it is recommended to store the medication at a temperature between 15 and 30 degrees Celsius, avoiding extremes of heat or cold.

Appearance

Yellow round film-coated tablets

Package unit

30 tablets/bottle, 300 tablets/bottle